FB102 Hits 29.6% Vitiligo Improvement in Phase 1b, Paving Path to Pivotal Trials
FBRX has more than doubled off its 52-week low of $9.1.
Summary
FB102 delivered a statistically significant 29.6% mean FVASI improvement at week 24 versus 7.9% for placebo (p=0.020) in a Phase 1b vitiligo study. The effect emerged early by Day 64 and continued to build after a 12-week treatment course. In patients with more extensive disease (baseline FVASI ≥0.75), the mean improvement jumped to 43.2% (p=0.006), with 58.8% achieving FVASI50 and 23.5% hitting FVASI75. Safety was clean — only mild-to-moderate adverse events, no severe events. This is the first detailed efficacy readout for FB102 in vitiligo and follows the FDA Fast Track designation for celiac disease in May. The data de-risks the program and supports advancement into pivotal trials, a meaningful catalyst for a $421M market cap biotech. The company recently closed a $162M offering, providing ample runway to fund next steps.
At the time of this announcement, FBRX was trading at $24.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $421.5M. The 52-week trading range was $9.10 to $35.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.